P-selectin Inhibitors
1 drugsAbout P-selectin
P-selectin (CD62P) is a cell adhesion molecule on activated platelets and endothelial cells that mediates leukocyte rolling along the endothelium, a key step in inflammation.
P-selectin is a therapeutic target for modulating inflammatory responses, though no genetic evidence currently links it directly to specific diseases. Its role in cell adhesion makes it relevant for conditions with excessive leukocyte recruitment.
P-selectin is targeted by one FDA-approved drug, ADAKVEO (Novartis), a biologic, for rare diseases. This single drug was approved in 2019.
Top P-selectin Drugs
Novartis is the only company with an approved drug targeting P-selectin.
Low competition may indicate high barriers to entry or limited market potential.
P-selectin Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets P-selectin, using biologic (other) modality.
The lack of modality diversity suggests an opportunity for small molecule or alternative approaches.
P-selectin Clinical Trials 13 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on P-selectin. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 0 | 1 | 1 | 0% |
| Phase 2 | 6 | 5 | 0 | 1 | 100% |
| Phase 3 | 2 | 0 | 0 | 2 | - |
| Phase 4 | 3 | 2 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
P-selectin Drug Approval Timeline (2019 - 2019)
The first and only drug was approved in 2019.
Recent approval but lack of follow-on drugs suggests market saturation or challenges in the target space.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on P-selectin. A trial counts if an approved drug acting on P-selectin is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.